Overview

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term outcomes remains challenging. This study will assess the safety, efficacy and tolerability of brexpiprazole as adjunctive therapy to protocol-specific open-label antidepressant therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Treatments:

Brexpiprazole
Citalopram
Dexetimide
Duloxetine Hydrochloride
Fluoxetine
Paroxetine
Sertraline
Venlafaxine Hydrochloride